New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Belinda Welsh

Dr Belinda Welsh

Rosacea – Smarter Diagnosis and State of the Art Care

A/Prof Ralph Audehm & Prof Genie Pedagogos

A/Prof Ralph Audehm & Prof Genie Pedagogos

The Role of SGLT2 Inhibitors in Preventing Dialysis

Prof Jason Ong

Prof Jason Ong

Syphilis is on the Rise – What GPs Can do to Turn it Around

Clinical A/Prof Greg Katsoulotos

Clinical A/Prof Greg Katsoulotos

COPD Cases

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 1 January 1970